Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
IPO Year: 2014
Exchange: NASDAQ
Website: atarabio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/9/2023 | Outperform → In-line | Evercore ISI | |
| 11/9/2023 | Buy → Neutral | H.C. Wainwright | |
| 11/9/2023 | $31.00 → $1.00 | Buy → Neutral | Mizuho |
| 7/20/2022 | $8.00 → $3.00 | Neutral → Sell | Citigroup |
| 7/13/2022 | $10.00 | Overweight → Neutral | JP Morgan |
| 7/13/2022 | $16.00 → $5.00 | Buy → Hold | Stifel |
| 5/10/2022 | $15.00 → $8.00 | Buy → Neutral | Citigroup |
| 1/3/2022 | $26.00 → $27.00 | Overweight | JP Morgan |